Top-Thema

15:16 Uhr +1,04%
Linde und Praxair starten neuen Anlauf zur Mega-​Fusion - Büchele geht

Lifshitz & Miller Law Firm Announces Investigation of Adeptus Health Inc., Avid Technology, Inc., Cempra, Inc., Clovis Oncology, Inc., Impax Laboratories, Inc., Ligand Pharmaceuticals Incorporated

Donnerstag, 01.12.2016 17:45 von

PR Newswire

NEW YORK, Dec.1, 2016 /PRNewswire/ --

Adeptus Health Inc. (ADPT)

Lifshitz & Miller announces investigation on behalf of ADPT investors concerning whether ADPT adequately disclosed its billing practices, especially with lower acuity level patients.

If you are an ADPT investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

Avid Technology, Inc. (AVID)

Lifshitz & Miller announces investigation on behalf of AVID investors concerning whether AVID adequately disclosed the launch of its new NEXIS solution product offerings and third quarter 2016 bookings and revenues.

If you are an AVID investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

Cempra, Inc. (CEMP)

Lifshitz & Miller announces investigation on behalf of CEMP investors concerning whether CEMP adequately disclosed the safety risks of CEMP's drug solithromycin for hepatotoxicity.

If you are a CEMP investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

Clovis Oncology, Inc. (CLVS)

Lifshitz & Miller announces investigation on behalf of CLVS investors concerning whether CLVS adequately disclosed test data for rociletinib, CLVS' lung cancer drug.

If you are a CLVS investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

Impax Laboratories, Inc. (IPXL)

Lifshitz & Miller announces investigation on behalf of IPXL investors concerning whether IPXL engaged in a scheme to fix generic drug prices with other pharmaceutical companies.

If you are a IPXL investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

Ligand Pharmaceuticals Incorporated (LGND)

Lifshitz & Miller announces investigation on behalf of LGND investors concerning whether LGND adequately disclosed certain deferred tax assets and outstanding convertible senior unsecured notes.

If you are an LGND investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

Pattern Energy Group Inc. (PEGI)

Lifshitz & Miller announces investigation on behalf of PEGI investors concerning whether PEGI adequately disclosed various transaction, process level and monitoring controls.

If you are a PEGI investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

Kandi Technologies Group, Inc. (KNDI)

Lifshitz & Millerannounces investigation on behalf of KNDIinvestors. The investigation concerns whether KNDIviolated federal securities laws by issuing false and misleading statements concerning KNDI’s financial results for the third quarter 2016.

If you are a KNDIinvestor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail atinfo@jlclasslaw.com.

ATTORNEY ADVERTISING. © 2016 Lifshitz & Miller. The law firm responsible for this advertisement is Lifshitz & Miller, 821 Franklin Avenue, Suite 209, Garden City, New York 11530, Tel: (516)493-9780. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact:

Joshua M. Lifshitz, Esq.
Lifshitz & Miller
Phone: 516-493-9780 
Facsimile: 516-280-7376
Email: info@jlclasslaw.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/lifshitz--miller-law-firm-announces-investigation-of-adeptus-health-inc-avid-technology-inc-cempra-inc-clovis-oncology-inc-impax-laboratories-inc-ligand-pharmaceuticals-incorporated-pattern-energy-group-inc-and-ka-300371505.html

SOURCE Lifshitz & Miller Law Firm